We also found that the level of S100A7A (HR = 1.71, 95%CI: 1.15–2.56, P = 0.0079), S100A12 (HR = 1.31, 95%CI: 1.04–1,64, P = 0.019), S100A14 (HR = 1.3, 95%CI: 1.02–1.65, P = 0.035), S100P (HR = 1.28, 95%CI: 1.01–1.62, P = 0.038) and S100G (HR = 1.27, 95%CI: 1.01–1.61, P = 0.043) predicted worse OS in mutant-p53-type EOC patients; however, S100A1 (HR = 0.66, 95%CI: 0.51–0.85, P = 0.0011), S100A13 (HR = 0.75, 95%CI: 0.6–0.94, P = 0.013) and S100A16 (HR = 0.64, 95%CI: 0.42–0.98, P = 0.08) were associated with better prognosis in ovarian cancer patients (Fig. 4). Here, S100A7A is linked to ovarian cancer.